AKYA AKOYA BIOSCIENCES INC

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at .

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .



Investor Contact:

Priyam Shah
 

Media Contact:

Christine Quern
EN
28/10/2024

Underlying

AKYAAKOYA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKOYA BIOSCIENCES INC

 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and NeraCare Enter into an Exclusive Global License ...

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease MARLBOROUGH, Mass. and FRANKFURT...

December 10, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Ak...

Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that Nature Methods, one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious , recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry’s largest installed base of 1300 instruments and...

December 9, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Reports Third Quarter 2024 Financial Results

Akoya Biosciences Reports Third Quarter 2024 Financial Results MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. “Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We p...

November 14, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with...

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial biology research accessible for every lab M...

November 5, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Bioscience to Report Third Quarter 2024 Financial Results on Nov...

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to . It is recommended to register at least a day in ad...

October 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch